Human stem cell trial on hold

The linkurl:Geron Corporation;http://www.geron.com/ linkurl:announced on Tuesday;http://www.geron.com/media/pressview.aspx?id=1187 (August 18) that its stem cell study of spinal cord injury -- the first-ever clinical trial using human embryonic stem cell (hESC)-based therapy -- has been put on hold by the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) pending the review of some newly submitted animal data. Human embryonic stem cellsImage: Wikimedia commons, Nissim Benvenisty

Jef Akst
Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf...

View full profile.


Learn about our editorial policies.

Aug 19, 2009
The linkurl:Geron Corporation;http://www.geron.com/ linkurl:announced on Tuesday;http://www.geron.com/media/pressview.aspx?id=1187 (August 18) that its stem cell study of spinal cord injury -- the first-ever clinical trial using human embryonic stem cell (hESC)-based therapy -- has been put on hold by the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) pending the review of some newly submitted animal data.
Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty
The study, which linkurl:received clearance;http://www.the-scientist.com/blog/display/55353/ on January 23 of this year after a 7 month hold by the FDA, aims to treat patients with severe spinal cord injury by injecting hESC-derived progenitors of neural support tissue into the spinal cord. So far, no patients have received the experimental therapy. Since Geron submitted its Investigational New Drug application to the FDA in March, 2008, the company has continued to pursue animal studies on the therapy (referred to as GRNOPC1), particularly with regard to increasing dosages and applying the therapy to...
New York Times



Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?